Pharos IBio Co (XKRX:388870) Debt-to-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Debt-to-Asset?

Pharos IBio Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₩113.78 Mil. Pharos IBio Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₩48.78 Mil. Pharos IBio Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was ₩21,016.56 Mil. Pharos IBio Co's debt to asset for the quarter that ended in Sep. 2024 was 0.01.

Pharos IBio Co Debt-to-Asset Historical Data

The historical data trend for Pharos IBio Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Debt-to-Asset Chart

Pharos IBio Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.11

0.04

0.02

0.01

Pharos IBio Co Quarterly Data
	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial					0.01	0.01	0.01	0.01	0.01

Competitive Comparison of Pharos IBio Co's Debt-to-Asset

For the Biotechnology subindustry, Pharos IBio Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharos IBio Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharos IBio Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Pharos IBio Co's Debt-to-Asset falls into.

Pharos IBio Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Pharos IBio Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(177.249	+	127.703)	/	29690.25
	=	0.01

Pharos IBio Co's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(113.775	+	48.779)	/	21016.561
	=	0.01

Pharos IBio Co (XKRX:388870) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Pharos IBio Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharos IBio Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR

Website

https://www.pharosibio.com

Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co Headlines

No Headlines